Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials

Purpose: Pembrolizumab and tislelizumab have demonstrated significant clinical benefits in first-line treatment for advanced NSCLC. However, no head-to-head clinical trial has ever compared the optimal choice. Therefore, we conducted an indirect comparison to explore the optimal choice for advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yimeng, Jia, Junting, Hao, Zhiying, Yang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318343/
https://www.ncbi.nlm.nih.gov/pubmed/37408759
http://dx.doi.org/10.3389/fphar.2023.1172969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318343/
https://www.ncbi.nlm.nih.gov/pubmed/37408759
http://dx.doi.org/10.3389/fphar.2023.1172969

Ejemplares similares